Stay updated on Faricimab in Neovascular AMD Clinical Trial
Sign up to get notified when there's something new on the Faricimab in Neovascular AMD Clinical Trial page.

Latest updates to the Faricimab in Neovascular AMD Clinical Trial page
- Check4 days agoNo Change Detected
- Check12 days agoChange DetectedMinor internal revision from v3.4.1 to v3.4.2 with no user-facing changes to study content; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check19 days agoChange DetectedThe page shows a site revision from v3.4.0 to v3.4.1. No changes to study content, eligibility criteria, or results are visible.SummaryDifference0.0%

- Check27 days agoChange DetectedMinor UI/metadata updates were applied, including enabling the glossary display and updating to revision v3.4.0, with removal of older QC status text and references to No FEAR Act data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check42 days agoChange DetectedRevision: v3.3.4 was added and v3.3.3 was removed. This update does not alter study details, eligibility criteria, or outcomes.SummaryDifference0.0%

- Check63 days agoChange Detected- Added a new Locations section listing participating sites by country/region (US states and international sites) and updated the revision to v3.3.3. - Removed the prior per-location blocks from v3.3.2 in favor of the consolidated Locations listing.SummaryDifference2%

- Check92 days agoChange DetectedPublications section now clarifies that some results publications are provided voluntarily by the data submitter and that others are auto-filled from PubMed. The revision version was updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

Stay in the know with updates to Faricimab in Neovascular AMD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Faricimab in Neovascular AMD Clinical Trial page.